Editor’s Choice: Differential risk of disease progression in CD

GIE Associate Editor, Dr. Lisa L. Strate, MD, MPH, highlights this article from the August issue “Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn’s disease” by Jacob E. Ollech, MD, et al.  Crohn's disease recurrence after ileocolonic resection is a common problem. It …

Continue reading Editor’s Choice: Differential risk of disease progression in CD

Editor’s Choice: Endoscopic focal cryoballoon ablation for esophageal squamous cell neoplasia

GIE Associate Editor, Dr. Fauze Maluf-Filho, highlights this article from the August issue “Prospective study of endoscopic focal cryoballoon ablation for esophageal squamous cell neoplasia in China” by Yan Ke, MD, et al.  This is one of the first and probably the largest clinical trial reporting on the treatment of moderate- and high-grade dysplasia of …

Continue reading Editor’s Choice: Endoscopic focal cryoballoon ablation for esophageal squamous cell neoplasia

Editor’s Choice: GEA vs MAC in high-risk patients undergoing ERCP

GIE Associate Editor, Dr. Sharmila Anandasabapathy, highlights this article from the April issue “A randomized controlled trial evaluating general endotracheal anesthesia versus monitored anesthesia care and the incidence of sedation-related adverse events during ERCP in high-risk patients” by Zachary L. Smith, DO, et al.  This is one of the few studies which compare, via a randomized …

Continue reading Editor’s Choice: GEA vs MAC in high-risk patients undergoing ERCP

Editor’s Choice: Role of interventional inflammatory bowel disease in the era of biologic therapy

GIE Senior Associate Editor, Dr. John R. Saltzman, MD, highlights this article from the February issue “Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement from the Global Interventional IBD Group” by Bo Shen, MD, et al.  There is an increasing recognition that Interventional (or therapeutic) inflammatory bowel disease …

Continue reading Editor’s Choice: Role of interventional inflammatory bowel disease in the era of biologic therapy

Editor’s Choice: Quality assurance of colonoscopy within the Dutch national colorectal cancer screening program

GIE Associate Editor, Dr. Lyndon V. Hernandez, MD MPH, highlights this article from the January issue “Quality assurance of colonoscopy within the Dutch national colorectal cancer screening program” by Maxime E.S. Bronzwaer, MD, et al.  In 2006, Barclay et al showed in their landmark study in The New England Journal of Medicine the association between …

Continue reading Editor’s Choice: Quality assurance of colonoscopy within the Dutch national colorectal cancer screening program

Editor’s Choice: The emerging role of histologic disease activity assessment in ulcerative colitis

GIE Editor-in-Chief, Dr. Michael Wallace, highlights this article from the December issue “The emerging role of histologic disease activity assessment in ulcerative colitis” by Rish K. Pai, MD, PhD, et al.  The decision about when to start and stop therapy for ulcerative colitis is increasingly made based on colonoscopy and histological assessment of activity ("treat …

Continue reading Editor’s Choice: The emerging role of histologic disease activity assessment in ulcerative colitis

Editor’s Choice: Screening for esophageal squamous cell carcinoma

Associate Editor, Dr. Fauze Maluf-Filho, highlights this article from the September issue “Screening for esophageal squamous cell carcinoma: recent advances” by Don C. Codipilly, MD, et al.  This study provides a thorough review of the current technologies (endoscopic and non-endoscopic) to screen for esophageal squamous cell carcinoma (ESCC). It also points out future directions for …

Continue reading Editor’s Choice: Screening for esophageal squamous cell carcinoma